

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>Applicant(s): Maurer, et al.</p> <p>Application No.: 10/019,199</p> <p>Filed: 12/20/2001</p> <p>Title: Methods for Preparation of Lipid-Encapsulated Therapeutic Agents</p> <p>Attorney Docket No.: INEX.P-005</p>	<p>Group Art Unit:</p> <p>Examiner:</p>
---	---

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Responsive to the Notification of Missing Requirements mailed March 1, 2002 for the above-captioned application, Applicants enclose a sequence listing in computer readable format and a paper copy of the sequence listing. Please amend the application by inserting the sequence listing at the appropriate location. The undersigned certifies that the content of the paper sequence listing and the computer readable sequence listing are the same and that no new matter has been added.

Respectfully Submitted,

March 29, 2002
Date

Marina S. Larson
Marina Larson
Attorney for Applicants
Reg. No. 32038
970 468 6600

Cert. under 37 CFR 1.8
This paper and the attachments named herein are being deposited with the United States Postal Service with sufficient postage as first class mail and addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on

3/29/02
Linda L. Orr
Name Linda L. Orr S:gr



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/019,199	Maurer	INEX.P-005

021121
 OPPEDAHN AND LARSON LLP
 P O BOX 5068
 DILLON, CO 80435-5068

INTERNATIONAL APPLICATION NO.	
PCT/CA00/00843	
I.A. FILING DATE	PRIORITY DATE
07/14/2000	07/15/1999

CONFIRMATION NO. 6234
 371 FORMALITIES LETTER



OC000000007563451

Date Mailed: 03/01/2002

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Indication of Small Entity Status
- Priority Document
- Biochemical Sequence Listing
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Small Entity Statement

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

• For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/019,199	PCT/CA00/00843	INEX.P-005

Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231